How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,492 results for

NIH Stroke Scale

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Periprocedural heparin use in acute ischemic stroke endovascular therapy: the TREVO 2 trial. (PubMed)

who did not receive periprocedural heparin (HEP-) while undergoing MERCI or TREVO clot retrieval.Of 173 patients, 58 (34%) received periprocedural heparin including 40 who received one preprocedural bolus (median 3000 units). Baseline characteristics among HEP+ and HEP- patients were similar except HEP+ patients had a lower NIH Stroke Scale (NIHSS) score (17 vs 19; p=0.04), lower IV tissue plasminogen activator use (38% vs 64%; p<0.01), and a higher median ASPECTS score (8.0 vs 7.0; p=0.02). HEP (...) Periprocedural heparin use in acute ischemic stroke endovascular therapy: the TREVO 2 trial. The use of periprocedural heparin has previously been reported to be safe and potentially beneficial during thrombectomy with older generation devices. We aimed to evaluate the safety and clinical outcomes of heparin use in the stent retriever era.A post hoc analysis of the TREVO 2 trial was performed comparing baseline characteristics and clinical outcomes between patients who received (HEP+) and those

2018 Journal of neurointerventional surgery

82. A randomized controlled study of intravenous fluid in acute ischemic stroke. (PubMed)

A randomized controlled study of intravenous fluid in acute ischemic stroke. To compare the outcome of patients with acute ischemic stroke who received or did not receive intravenous fluid.This study was a prospective, multicenter, randomized, open-label trial with blinded outcome assessment. We enrolled acute ischemic stroke patients without dehydration aged between 18 and 85 years with NIH Stroke Scale score (NIHSS) score from 1 to 18 who presented within 72h after onset. Patients were (...) -IV fluid group and 3.3% of the IV fluid group (p=0.02). Predictors of neurological deterioration were higher NIHSS score, higher plasma glucose, and increased pulse rate. There was no difference in the primary efficacy outcome, NIHSS≤4 at day 7, 83.3% vs 86.7%, p=0.61 or secondary efficacy outcomes.Administration of 0.9% NaCl 100ml/h for 72h in patients with acute ischemic stroke is safe and may be associated with a reduced risk of neurological deterioration. These study findings support the use

2018 Clinical neurology and neurosurgery

83. SURE 18 Registry -Asahi Chikai Black 18 in LVO Stroke

and unable to attend to own bodily needs without assistance Severe disability; bedridden, incontinent and requiring constant nursing care and attention Dead Change in NIH Stroke Scale (NIHSS) [ Time Frame: 24 hours ] The score for each ability is a number between 0 (normal functioning) to 4 (completely impaired). The NIHSS has 11 different items and the highest possible score is 42. The higher the score, the more impaired a stroke patient is. Number of neurovascular guidewires required per case [ Time (...) SURE 18 Registry -Asahi Chikai Black 18 in LVO Stroke SURE 18 Registry -Asahi Chikai Black 18 in LVO Stroke - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. SURE 18 Registry -Asahi Chikai Black 18 in LVO

2018 Clinical Trials

84. Early Administration of Edoxaban After Acute Ischemic Stroke in Patients With Non-valvular Atrial Fibrillation

of symptomatic or asymptomatic recurrent ischemic strokes on DWI Secondary Outcome Measures : Recurrent ischemic lesions [ Time Frame: until Day 10−14 ] The incidence rate of recurrent ischemic lesions with significant clinical worsening (≥NIHSS 4) The National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS) is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 (...) (≥ 24 hours) that is clinically judged by the investigator not to be attributable to non-ischemic etiology (≥NIHSS 2) The National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS) is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score

2018 Clinical Trials

85. Insulin resistance and clinical outcomes after acute ischemic stroke. (PubMed)

assessment of insulin resistance (HOMA-IR) score was calculated using fasting blood glucose and insulin levels measured 8.3 ± 7.8 days after onset. Study outcomes were neurologic improvement (≥4-point decrease in NIH Stroke Scale score or 0 at discharge), poor functional outcome (modified Rankin Scale score of ≥3 at 3 months), and 3-month prognosis (stroke recurrence and all-cause mortality). Logistic regression analysis was used to evaluate the association of the HOMA-IR score with clinical outcomes.The (...) Insulin resistance and clinical outcomes after acute ischemic stroke. In this study, we aimed to determine whether insulin resistance is associated with clinical outcomes after acute ischemic stroke.We enrolled 4,655 patients with acute ischemic stroke (aged 70.3 ± 12.5 years, 63.5% men) who had been independent before admission; were hospitalized in 7 stroke centers in Fukuoka, Japan, from April 2009 to March 2015; and received no insulin therapy during hospitalization. The homeostasis model

2018 Neurology

86. Racial disparities in refusal of stroke thrombolysis in Chicago. (PubMed)

(adjusted odds ratio [OR] 2.5, 95% confidence interval [CI] 1.3-4.6), self-pay status (adjusted OR 3.23, 95% CI 1.2-8.71), prior stroke (adjusted OR 2.11, 95% CI 1.14-3.90), age (adjusted OR 1.04, 95% CI 1.02-1.07), and NIH Stroke Scale score (adjusted OR 0.94, 95% CI 0.90-0.99).Among tPA-eligible patients with AIS in Chicago, over 7% refused tPA. Refusal was more common in black patients and accounted for the apparent lower rates of tPA use in black vs nonblack patients. Further research is needed (...) Racial disparities in refusal of stroke thrombolysis in Chicago. To evaluate race differences in tissue plasminogen activator (tPA) refusal among eligible patients with acute ischemic stroke (AIS) in Chicago.Using the Get With The Guidelines-Stroke registry data from 15 primary stroke centers between January 2013 and June 2015, we performed a retrospective analysis of patients with AIS presenting to the emergency department within 4.5 hours from symptom onset. Patient or proxy refusal

2018 Neurology

87. Usefulness of ADAMTS13 to predict response to recanalization therapies in acute ischemic stroke. (PubMed)

, NIH Stroke Scale score, and time from stroke onset.Patients who achieved tPA-induced recanalization had higher baseline ADAMTS13 activity (78.1% [68%-88%] vs 70.1% [61%-79%], p = 0.021). In logistic regression analysis, ADAMTS13 activity >75% was an independent predictor of recanalization (odds ratio = 6.76 [1.52-30.02], p = 0.012), together with absence of early ischemic signs and Oxfordshire Community Stroke Project classification. Regarding endovascular therapies, a reduced ADAMTS13 (...) Usefulness of ADAMTS13 to predict response to recanalization therapies in acute ischemic stroke. We aimed to analyze ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) in relation to arterial recanalization in patients treated with IV tissue plasminogen activator (tPA) and in relation to futile recanalization in patients treated with mechanical thrombectomy.Acute ischemic stroke patients (n = 108) with documented arterial occlusions treated with IV-tPA

2018 Neurology

88. Challenge of intravascular volume assessment in acute ischemic stroke. (PubMed)

in the emergency department. Patients with NIH stroke scale ≥4 within 12 h of symptom onset were included. A trained ultrasonographer performed bi-dimensional imaging of the IVC with passive respiration to determine the percent inspiratory collapse and maximum diameter. We defined low intravascular volume as >50% IVC collapse and a maximal diameter < 2.1 cm. Analysis was limited to patients with confirmed ischemic stroke.There were 42 patients, of whom 31 had confirmed acute ischemic stroke. The mean age (...) was 65 ± 15 years, 52% were female, and 71% were hypertensive. The median NIH stroke scale score was 7 (IQR 5-15). Based on IVC ultrasound, low intravascular volume was present in 63% (95% CI 44-80%) of patients. A higher proportion of hypertensive patients had low intrasvascular volume (72% vs. 33%). There was poor correlation between IVC assessment of intrasvascular volume and blinded clinician assessment or laboratory markers of dehydration.The majority of ED acute ischemic stroke patients

2018 American Journal of Emergency Medicine

89. Mean Platelet Volume, C-Reactive Protein, and Prognosis in Patients with Acute Ischemic Stroke Following Intravenous Thrombolytic Treatment (PubMed)

received IV thrombolytic treatment. Clinical data were retrieved from electronic medical records. MPV, CRP, and National Institutes of Health (NIH) Stroke Scale and the modified Rankin Scale (MRS) scores for physical disability were recorded. RESULTS Of the 129 patients, 65.9% were men, and more than half received IV thrombolytic treatment within between 3-4.5 hours. The NIH Stroke Scale scores at 24 hours and at three months after hospital admission were compared with the NIH Stroke Scale scores (...) on hospital admission. A significant correlation was found between the MPV values at 24 hours (r=0.221; p=0.012) and at three months after hospital admission (r=196; p=0.026). There was a significant correlation between CRP values at 24 hours (r=0.224; p=0.021), the difference in NIH Stroke Scale score between 24 hours and three months (r=0.249; p=0.005), and the MPV score at three months (r=0.186; p=0.035). CONCLUSIONS MPV and CRP values were significantly associated with improvement in the NIH Stroke

Full Text available with Trip Pro

2018 Medical science monitor : international medical journal of experimental and clinical research

90. Internet-based CBT After Stroke Pilot

attempts are excluded History of schizophrenia or schizoaffective disorder Active participation in face-to-face psychotherapy prior to stroke Patients with a history of dementia are excluded Patients with aphasia, defined as a score of 1 or greater on NIH Stroke Scale Item 9 are excluded. Patients without regular internet access through a computer, tablet or smartphone are excluded. Subjects requiring long-term inpatient nursing care are excluded. For patients enrolled as inpatients, individuals being (...) Internet-based CBT After Stroke Pilot Internet-based CBT After Stroke Pilot - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Internet-based CBT After Stroke Pilot (iSAD) The safety and scientific validity

2018 Clinical Trials

91. Feasibility of the Lee Silverman Voice Treatment®-BIG Intervention in Stroke

by medical records Has more than a moderate stroke (NIH Stroke Scale > 20) Can read and write English. To ensure participants can understand instructions in clinic and home exercise sessions Exclusion Criteria: More than moderate motor deficits (Fugl-Meyer UE Assessment < 32/66) More than mild cognitive impairment (Mini-Mental Status Examination < 24) More than mild balance deficits (Berg Balance Scale <45) Minimal or no impairments from their stroke (NIH Stroke Scale < 6) Currently receiving (...) ) [ Time Frame: 4 weeks ] The Performance Assessment of Self-Care Skills (PASS) assesses basic self-care and instrumental activities of daily living. Subscales: Independence, Safety, Adequacy (minimum: 0, maximum: 3). There is no total score reported. Change from baseline in PROMIS-43 [ Time Frame: 4 weeks ] General assessment of quality of life and participation in daily life. Assessment is from the standardized NIH Toolbox. T-scores are reported on scale of 0-100 (50 is average). Change from baseline

2018 Clinical Trials

92. Cerebrolysin REGistry Study in Stroke

with Cerebrolysin Observation criteria: Signed Informed Consent Clinical diagnosis of acute ischemic stroke confirmed by imaging Moderate to severe neurological deficits with NIH Stroke Scale (NIHSS) 8 to 15, both inclusive No prior stroke No prior disability Patient's independence prior to stroke onset (pre-morbid mRS of 0 or 1) Reasonable expectation of successful follow-up (max. 100 days) The study follows the recommendations of the Principles for Good Research on Comparative Effectiveness (GRACE). In order (...) symptoms to death. Secondary Outcome Measures : Ordinal NIH Stroke Scale (NIHSS) at 21 days and 3 months after stroke onset [ Time Frame: Day 21 and 3 months ] The National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS) is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function

2018 Clinical Trials

93. Cortical Priming to Optimize Gait Rehabilitation Post Stroke

Collaborator: National Institutes of Health (NIH) Information provided by (Responsible Party): University of Illinois at Chicago Study Details Study Description Go to Brief Summary: Over four million stroke survivors currently living in the United States are unable to walk independently in the community. To increase the effectiveness of gait rehabilitation, it is critical to develop therapies that are based on an understanding of brain adaptations that occur after stroke. This project will be the first (...) ordinal scale ranging from 0 to 4, with 0 indicating the lowest level of function and 4 the highest level of function. Tasks such as standing with eyes closed, one leg stance etc are included. Change in Quality of life measures [ Time Frame: Change from baseline to immediately after training and baseline to 3 months follow up ] QOL will be measured with the Stroke Impact Scale (SIS). The SIS is a stroke-specific self-reported health status measure. Change in cortical excitability of leg muscles using

2018 Clinical Trials

94. China Antihypertensive Trial in Acute Ischemic Stroke II

pressure (BP) between 140-200 mmHg at randomization. Patients with extracranial or intracranial artery stenosis (≥70%) in both sides or the affected side, NIH Stroke Scale score of ≥21, Glasgow Coma Scale score <8, preceding moderate or severe dependency (modified Rankin scale score 3-5), revascularization, intravenous thrombolytic therapy or mechanical thrombectomy will be excluded. All eligible patients will discontinue their home antihypertensive medications. Patients admitted within 24 hours (...) Collaborators: Beijing Tiantan Hospital Soochow University Information provided by (Responsible Party): Jiang He, MD, PhD, Tulane University Study Details Study Description Go to Brief Summary: The investigators propose to conduct a multicenter randomized trial to test the primary hypothesis of whether early antihypertensive treatment starting between the first 24-48 hours after the onset of an acute ischemic stroke will reduce the risk of composite case-fatality and major disability (modified Rankin Scale

2018 Clinical Trials

95. Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke

(such as hemianopia) preventing full view of the screen Anesthesia or neglect in the affected arm, or visual hemineglect (score of 2 on the NIH Stroke Scale Extinction and Inattention subtest). Participation in another study on the affected arm within 6 weeks of enrollment or any pharmacological study Inability to understand or follow commands in English due to aphasia or other reason Diffuse or multifocal infarcts Substantial arm pain preventing participation for 90 minutes a day New spasticity treatment (...) Sponsor: Northwestern University Collaborators: Shirley Ryan AbilityLab National Institutes of Health (NIH) Information provided by (Responsible Party): Marc Slutzky, Northwestern University Study Details Study Description Go to Brief Summary: The purpose of the study is to explore the feasibility of using a wearable device, called a myoelectric-computer interface (MCI), to improve arm movement in people who have had a stroke. Impaired arm movement after stroke is caused not just by weakness, but also

2018 Clinical Trials

96. Game-Based Home Exercise Programs in Chronic Stroke: A Feasibility Study

: Baseline, 8 weeks ] Angle (degrees) of the shoulder joint as measured by a goniometer Change from baseline in the bicep strength [ Time Frame: Baseline, 8 weeks ] Muscle strength of the biceps muscle as measured by manual muscle testing (scale 0-5) Change from baseline in the PROMIS-29 [ Time Frame: Baseline, 8 weeks ] General assessment of quality of life and participation in daily life. Assessment is from the standardized NIH Toolbox. T-scores are reported on scale of 0-100 (50 is average). Mini (...) /tension. There are no normative values Range of Motion Screening [ Time Frame: Screening ] Participant will be screened to see if they have the minimal movement at the shoulder and elbow. Berg Balance Scale [ Time Frame: Screening ] Assessment of balance ability. Score range is 0-56. Cut-off for screening is 45 Change from baseline in the Fugl-Meyer Assessment - Upper Extremity [ Time Frame: Baseline, 8 weeks ] Assessment of upper extremity function post-stroke. Scale ranges from 0-66. Eligibility

2018 Clinical Trials

97. Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial

deficits. Aged 18 to 80 years,male or famale. NIH Stroke Scale(NIHSS)scores of 4 to 25. Treatment 4.5 to 6 hours after stroke onset.(Stroke onset time is defined as the last time a patient with no clinical neurological deficit,for patients who wake up with stroke symptoms, consider that stroke occurs when the patient begins to fall asleep). The symptoms of stroke last at least 30 minutes without significant improvement before treatment. CT showed negative or signs of early infarction. Patients (...) . Secondary Outcome Measures : Proportion of Neurological Improvement [ Time Frame: 90 days ] Proportion of patients achieving a NIHSS(national institutes of health stroke scale) ≦1 or reduction of ≥4 NIHSS points at 24 hours after treatment. Scores of Neurological Improvement [ Time Frame: 24 hours ] NIHSS changes from baseline at 24 hours after treatment Index Long-term Change from Baseline of Barthel Index [ Time Frame: 90 days ] Barthel Index(which assesses the ability to perform activities of daily

2018 Clinical Trials

98. Therapies for Recovery of Hand Function After Stroke

University Kessler Foundation National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Information provided by (Responsible Party): Jayme Knutson, MetroHealth Medical Center Study Details Study Description Go to Brief Summary: After a stroke, it is very common to lose the ability to open the affected hand. The purpose of this study is to compare the effects of three different therapies on recovery of hand function after stroke (...) hand under the guidance of a trained therapist. Outcome Measures Go to Primary Outcome Measures : Box and Blocks Test (BBT) change [ Time Frame: 0 to 12 weeks, 0 to 36 weeks ] The BBT counts how many blocks a patient can pick up, move over a barrier, and release in 60 seconds. Secondary Outcome Measures : Stroke Upper Limb Capacity Scale (SULCS) change [ Time Frame: 0 to 12 weeks, 0 to 36 weeks ] The SULCS is a 10-item test in which participants are given a score of 0 or 1 on their performance

2018 Clinical Trials

99. Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation

a visual scale from 0 (worst thinkable health condition) to 100 (best thinkable health condition) to report an overall measure. Compliance to NOAC [ Time Frame: 2-, 3-, 5-, and 10-years ] Adherence to assigned NOAC therapy will be assessed through the National Prescription Registries. Changes in neurological status based on National Institute of Health (NIH) Stroke scale score [ Time Frame: 12 months ] Assessed by the NIH stroke scale at baseline and 12 month follow-up. A scale to quantify (...) the neurological impairment caused by a stroke. It includes 11 items, each of which scores a specific ability between 0 to 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores are summed to calculate the total NIH Stroke Scale score, that can range from 0 to 42, with 0 being no symptoms. Score 0: No stroke symptoms Score 1-4: Minor stroke Score 5-15: Moderate stroke Score 16-20

2018 Clinical Trials

100. Antiplatelet vs R-tPA for Acute Mild Ischemic Stroke

-2) [ Time Frame: 90±7 days ] change in NIH Stroke Scale score compared with baseline [ Time Frame: 24 hours ] incidence of early neurological improvement [ Time Frame: 24 hours ] more than 2 NIH Stroke Scale score decrease compared with baseline Incidence of early neurological deterioration [ Time Frame: 7 days ] more than 2 NIH Stroke Scale score increase (not result of cerebral hemorrhage) compared with baseline occurrence of stroke or other vascular events [ Time Frame: 90±7 days ] proportion (...) Antiplatelet vs R-tPA for Acute Mild Ischemic Stroke Antiplatelet vs R-tPA for Acute Mild Ischemic Stroke - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Antiplatelet vs R-tPA for Acute Mild Ischemic Stroke

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>